Publikasjoner
NIBIOs ansatte publiserer flere hundre vitenskapelige artikler og forskningsrapporter hvert år. Her finner du referanser og lenker til publikasjoner og andre forsknings- og formidlingsaktiviteter. Samlingen oppdateres løpende med både nytt og historisk materiale. For mer informasjon om NIBIOs publikasjoner, besøk NIBIOs bibliotek.
2018
Forfattere
Arne Verstraeten Elena Gottardini Nicolas Bruffaerts Bruno de Vos Elena Vanguelova Fabiana Cristofolini Sue Benham Pasi Rautio Liisa Ukonmaanaho Päivi Merilä Peter Waldner Marijke Hendrickx Gerrit Genouw Peter Roskams Nathalie Cools J Neirynck Anita Nussbaumer Mathias Neumann Nicholas Clarke Volkmar Timmermann Karin Hansen Hans-Peter Diettrich Manuel Nicolas Maria Schmitt Anne Thimonier Katrin Meusburger Silvio Schueler Anna KowalskaSammendrag
Det er ikke registrert sammendrag
Sammendrag
Det er ikke registrert sammendrag
Sammendrag
Det er ikke registrert sammendrag
Sammendrag
Det er ikke registrert sammendrag
Sammendrag
Det er ikke registrert sammendrag
Forfattere
Even Klyve Dahl Hetron Mweemba Munang'andu Andre van Eerde Jihong Liu Clarke Øystein EvensenSammendrag
Det er ikke registrert sammendrag
Forfattere
Andre van Eerde Johanna Gottschamel Ralph Bock Kristine Eraker Aasland Hansen Hetron Mweemba Munangandu Henry Daniell Jihong Liu ClarkeSammendrag
Dengue fever is a mosquito (Aedes aegypti) ‐transmitted viral disease that is endemic in more than 125 countries around the world. There are four serotypes of the dengue virus (DENV 1‐4) and a safe and effective dengue vaccine must provide protection against all four serotypes. To date, the first vaccine, Dengvaxia (CYD‐TDV), is available after many decades’ efforts, but only has moderate efficacy. More effective and affordable vaccines are hence required. Plants offer promising vaccine production platforms and food crops offer additional advantages for the production of edible human and animal vaccines, thus eliminating the need for expensive fermentation, purification, cold storage and sterile delivery. Oral vaccines can elicit humoral and cellular immunity via both the mucosal and humoral immune systems. Here, we report the production of tetravalent EDIII antigen (EDIII‐1‐4) in stably transformed lettuce chloroplasts. Transplastomic EDIII‐1‐4‐expressing lettuce lines were obtained and homoplasmy was verified by Southern blot analysis. Expression of EDIII‐1‐4 antigens was demonstrated by immunoblotting, with the EDIII‐1‐4 antigen accumulating to 3.45% of the total protein content. Immunological assays in rabbits showed immunogenicity of EDIII‐1‐4. Our in vitro gastrointestinal digestion analysis revealed that EDIII‐1‐4 antigens are well protected when passing through the oral and gastric digestion phases but underwent degradation during the intestinal phase. Our results demonstrate that lettuce chloroplast engineering is a promising approach for future production of an affordable oral dengue vaccine.
Sammendrag
Det er ikke registrert sammendrag
Sammendrag
Det er ikke registrert sammendrag
Forfattere
Mihaela-Olivia Dobrica Catalin Lazar Lisa Paruch Andre van Eerde Jihong Liu Clarke Catalin Tucureanu Iuliana Caras Sonya Ciulean Adrian Onu Vlad Tofan Alexandru Branzan Stephan Urban Crina Stavaru Norica Branza-NichitaSammendrag
Hepatitis B Virus (HBV) infection can be prevented by vaccination. Vaccines containing the small (S)envelope protein are currently used in universal vaccination programs and achieve protective immuneresponse in more than 90% of recipients. However, new vaccination strategies are necessary for successfulimmunization of the remaining non- or low-responders. We have previously characterized a novel HBVchimeric antigen, which combines neutralization epitopes of the S and the preS1 domain of the large (L)envelope protein (genotype D). The S/preS121–47chimera produced in mammalian cells and Nicotianabenthamiana plants, induced a significantly stronger immune response in parenterally vaccinated micethan the S protein. Here we describe the transient expression of the S/preS121–47antigen in an edibleplant, Lactuca sativa, for potential development of an oral HBV vaccine. Our study shows that oral admin-istration of adjuvant-free Lactuca sativa expressing the S/preS121–47antigen, three times, at 1lg/dose,was sufficient to trigger a humoral immune response in mice. Importantly, the elicited antibodies wereable to neutralize HBV infection in an NTCP-expressing infection system (HepG2-NTCP cell line) moreefficiently than those induced by mice fed on Lactuca sativa expressing the S protein. These results sup-port the S/preS121–47antigen as a promising candidate for future development as an edible HBV vaccine.